Research literature

5-Amino-1MQ Research Explained: What the Mouse Data Show and What They Do Not

Published October 18, 2026 · 6 min read

5-Amino-1MQ shows up in plenty of “fat loss” and “metabolism” marketing. Behind the buzz sits a small body of early research, and most of it traces back to one paper. Here is what that paper actually did, and where it stops.

The short version

5-Amino-1MQ is a small molecule that blocks an enzyme called NNMT. In a 2018 study, researchers gave it to obese mice for 11 days, and the mice lost weight and fat tissue without eating less. That is the whole in-animal story. We found no published human clinical trial in our literature search. So everything here is a proof-of-concept result in mice, which is a long way from knowing whether it would do anything in people.

What is 5-amino-1MQ?

Its full name is 5-amino-1-methylquinolinium. Despite how it is often sold, it is not a peptide. It is a small, membrane-permeable molecule, which means it can get inside cells. Its target is nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular energy metabolism. The 2018 paper describes it as a potential new target for obesity and type 2 diabetes.

Blocking NNMT is thought to affect two molecules cells use to run their energy chemistry: NAD+ and SAM. In cultured fat cells, the study found that NNMT inhibitors lowered the enzyme’s reaction product (1-methylnicotinamide), raised intracellular NAD+ and SAM, and suppressed lipogenesis, the making of fat.

Related lab results (full disclosure: DAAVY Research is our own company): 5-Amino 1MQ 500 mg COA (99.88% purity) · COA library, every current lot.

What did the mouse study do?

The key paper is Neelakantan and colleagues, published in Biochemical Pharmacology in 2018. The authors tested a series of NNMT inhibitors, checking whether they could cross cell membranes, whether they were selective for NNMT over related enzymes, and what they did in cultured fat cells. Then they picked 5-amino-1MQ for an animal test.

• Animals: male C57BL/6 mice fed a high-fat diet for 16 weeks, with 9 mice per group.
• Treatment: subcutaneous injections for 11 days, versus saline injections in controls.
• Body weight: treated mice lost about 5% of their body weight while control mice gained about 1.4%.
• Fat tissue: epididymal white fat weighed about 35% less than in controls, and fat cells were more than 30% smaller by area.
• Cholesterol: total plasma cholesterol was about 30% lower.
• Food intake: no significant difference, so the weight change was not simply from eating less.

The authors also reported no observable adverse effects, and the compound was selective: it did not inhibit related methyltransferases or the enzymes that recycle NAD+.

Why this is not strong evidence

Honestly, the paper reads as a promising first step, and the details matter:

• It is small and short. Nine mice per group, 11 days, males only. The dose was chosen after a pilot in just two mice.
• The key mechanism was not measured in the animals. The NAD+ and SAM changes were seen in cultured cells. The authors left testing them in the animals’ fat tissue for future work.
• Some data are missing. Triglycerides were excluded because blood-sample damage interfered with the assay, and cholesterol was compared against reference values rather than a normal-diet control group.
• Route and form matter. The compound was injected. Oral absorption was not tested here, so results say nothing about other forms.
• Mice are not people. Many compounds that shrink fat in diet-induced obese mice never do anything comparable in humans.
• No human safety record. An absence of observed adverse effects over 11 days in a small mouse study is not a safety profile.

The takeaway

5-Amino-1MQ is a reasonable subject for early metabolism research: it hits an interesting target, it is selective in cell tests, and one small mouse study found effects worth following up. It is also an example of why “the research shows” deserves a follow-up question. Which research, in what animal, for how long, and was it ever tested in people? Here the honest answers are one paper, mice, 11 days, and no. For help reading study design, see How to Read a Clinical Trial Result.

Sources

• Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141–152. doi:10.1016/j.bcp.2017.11.007. (Full text: PMC5826726.)

Related reading

• How to Read a Clinical Trial Result
• Why “It Worked for Me” Isn’t Evidence
• Tesamorelin Trial Results Explained
• Glossary

← Back to all articles